ZIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zide, and when can generic versions of Zide launch?
Zide is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in ZIDE is hydrochlorothiazide. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zide
A generic version of ZIDE was approved as hydrochlorothiazide by PRINSTON INC on March 29th, 2002.
Summary for ZIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 134 |
Patent Applications: | 3,809 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ZIDE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ZIDE
US Patents and Regulatory Information for ZIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solvay | ZIDE | hydrochlorothiazide | TABLET;ORAL | 083925-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |